US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inspire Corporate Bond ETF

24.05

+0.04000.17%

Post-market: 24.050.00000.00%16:04 EDT

Volume:295.40K

Turnover:7.08M

Market Cap:387.21M

PE:- -

High:24.08

Open:24.08

Low:23.90

Close:24.01

Loading ...

Overview Company News Filings

Marex Stock, Clearwater Analytics Graduate To Elite Level Of IBD Sector Leaders

TPG Appoints Kathy Elsesser as New Independent Director

IBD Stock Of The Day: Can Sea Stock Build Off Its 162% 2024 Rally?

Comfort Systems Stock, Emcor, Freshpet, 16 Other Stocks Enter IBD Watchlists

Howmet, IBD Stock Of The Day, Flashes Buy Signal After Nearly Tripling

AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Planet Fitness, IBD Stock Of The Day, Flexes Near Buy Point With Membership Growth

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Boston Scientific Tops All-Time High: See New Names On IBD 50, IPO Leaders, More

Stock Market Seeks Direction, Grasps For Possible Support Levels; These IBD 50 Stocks Approach Buy Points

IBD Stock Of The Day: Netflix Tests Key Level Ahead Of Q4 Earnings

Nvidia, Netflix, TSMC New To These IBD Lists: Check Out Names On IBD 50, Stock Spotlight And More

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Press Release: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Baker Hughes, Nvidia Lead 18 IBD Watchlist Adds: Build Your Growth Stock List With These Screens

Spyre Therapeutics Announces Grants of Inducement Awards

Why Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed Yesterday

Carpenter Technology Stock Receives IBD Stock Rating Upgrade

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IBD/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":24.05,"timestamp":1751400000000,"preClose":24.01,"halted":0,"volume":295401,"hourTrading":{"tag":"盘后","latestPrice":24.05,"preClose":24.05,"latestTime":"16:04 EDT","volume":4,"amount":96.2,"timestamp":1751400251773},"delay":0,"floatShares":16100000,"shares":16100000,"eps":0,"marketStatus":"Closed","change":0.04,"latestTime":"07-01 16:00:00 EDT","open":24.08,"high":24.08,"low":23.9,"amount":7084627.244724,"amplitude":0.007497,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751443200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":24.01,"sharesOutstanding":16100000,"nav":23.93,"aum":385325099.69,"dividendRate":0.041996,"bidAskSpread":0.00295,"postHourTrading":{"tag":"盘后","latestPrice":24.05,"preClose":24.05,"latestTime":"16:04 EDT","volume":4,"amount":96.2,"timestamp":1751400251773},"volumeRatio":5.415353},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":16100000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":5.415353,"shares":16100000,"dividePrice":1.01,"high":24.08,"amplitude":0.007497,"preClose":24.01,"low":23.9,"week52Low":22.84,"pbRate":"--","week52High":25.49,"institutionHeld":0,"latestPrice":24.05,"eps":0,"divideRate":0.041996,"volume":295401,"delay":0,"ttmEps":0,"open":24.08,"prevYearClose":23.44,"prevWeekClose":23.92,"prevMonthClose":24.01,"prevQuarterClose":24.01,"fiveDayClose":24,"twentyDayClose":23.74,"sixtyDayClose":23.86},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503609971","title":"Marex Stock, Clearwater Analytics Graduate To Elite Level Of IBD Sector Leaders","url":"https://stock-news.laohu8.com/highlight/detail?id=2503609971","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503609971?lang=en_us&edition=fundamental","pubTime":"2025-01-16 07:08","pubTimestamp":1736982532,"startTime":"0","endTime":"0","summary":"See which stocks have just been added to – or removed from – IBD’s stock lists, including the IBD 50, Sector Leaders, IBD Big Cap 20 and IPO Leaders.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate3-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate3-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/marex-stock-clearwater-analytics-graduate-to-ibd-sector-leaders-level/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IBD"],"gpt_icon":0},{"id":"2503560895","title":"TPG Appoints Kathy Elsesser as New Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2503560895","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503560895?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:15","pubTimestamp":1736975700,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO & FORT WORTH, Texas, January 15, 2025----TPG Inc. , a leading global alternative asset management firm, announced today that Kathy Elsesser has joined its Board of Directors  as an independent director, effective immediately.\"On behalf of the Board and leadership team, we are pleased to welcome Kathy to the TPG Board,\" said Jim Coulter, Founding Partner and Executive Chairman of TPG. \"Kathy brings a deep understanding of our industry from her years on Wall Street and her appointment is part of our long-term plan for corporate governance by a majority independent Board of Directors.\". \"A trusted advisor and strategic partner to CEOs, founders, entrepreneurs, and corporate boards, Kathy is an industry leader with deep relationships and strong commercial instincts,\" said Jon Winkelried, Chief Executive Officer. \"We look forward to working closely with Kathy and know that our Board will benefit from her judgment and expertise.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tpg-appoints-kathy-elsesser-independent-211500558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443895.HKD","BK4588","LU2237443978.SGD","LU1668664300.SGD","LU2237438978.USD","LU2237443382.USD","IE00BFXG1179.USD","BK4552","BK4550","IE00B19Z3581.USD","BK4504","BK4585","IE0004091025.USD","IE00B19Z3B42.SGD","IBD","IE0004086264.USD","LU1791807156.HKD","BK4533","LU2237443549.SGD","IE00BSNM7G36.USD","TPG","LU0106831901.USD","IE0034235188.USD","BK4516","IE0002270589.USD","BK4127","BK4135","LU2237443465.HKD","LU2237443622.USD"],"gpt_icon":0},{"id":"2503605622","title":"IBD Stock Of The Day: Can Sea Stock Build Off Its 162% 2024 Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503605622","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503605622?lang=en_us&edition=fundamental","pubTime":"2025-01-16 00:56","pubTimestamp":1736960180,"startTime":"0","endTime":"0","summary":"Sea stock is bouncing up from it 50-day line as the Shopee parent company hopes to build off a 162% rally in 2024.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2025/01/sotd-for-01-15-2025-desktop-150x150.png","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/01/sotd-for-01-15-2025-desktop-150x150.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/ibd-stock-of-the-day/sea-stock-ecommerce-stock-of-the-day/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["SG9999002604.SGD","PDD","LU0231483743.USD","BABA","LU0051755006.USD","LU0348825331.USD","BK4527","LU1719994722.HKD","09988","LU0918141887.USD","LU0072462343.USD","BK4579","LU0516422952.EUR","HK0000306701.USD","BK4551","SG9999002406.SGD","LU0979878070.USD","LU0572944931.SGD","LU0683595622.HKD","SE","LU0052750758.USD","LU1242518857.USD","LU1769817096.USD","BGSX","LU0348805143.USD","LU0823038988.USD","LU0823397103.USD","SG9999014674.SGD","LU1956131251.USD","LU0589944569.HKD","LU1046422090.SGD","LU0532188223.SGD","LU1868837565.USD","LU0823426480.USD","LU0708995583.HKD","LU0128525689.USD","SG9999002620.SGD","LU0348788117.USD","LU1048588211.SGD","LU0307460666.USD","LU0140636845.USD","SG9999002679.SGD","LU1880383440.USD","LU0588546209.SGD","LU0605514214.HKD","LU0821914370.USD","LU0797268264.HKD","LU0633140560.USD","LU1688375341.USD","IBD"],"gpt_icon":1},{"id":"2503636445","title":"Comfort Systems Stock, Emcor, Freshpet, 16 Other Stocks Enter IBD Watchlists","url":"https://stock-news.laohu8.com/highlight/detail?id=2503636445","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503636445?lang=en_us&edition=fundamental","pubTime":"2025-01-15 07:10","pubTimestamp":1736896259,"startTime":"0","endTime":"0","summary":"Here’s a list of all the top-rated growth stocks that have just been added to the IBD 50, IBD Big Cap 20, Sector Leaders, Stock Spotlight and IPO leaders.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate5-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate5-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/comfort-systems-stock-emcor-freshpet-enter-ibd-watchlists/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4212","LU0053671581.USD","FRPT","LU1941712264.USD","IBD","LU1941712348.USD","LU0029874061.USD","LU0266013472.USD","LU0128526141.USD"],"gpt_icon":0},{"id":"2503500009","title":"Howmet, IBD Stock Of The Day, Flashes Buy Signal After Nearly Tripling","url":"https://stock-news.laohu8.com/highlight/detail?id=2503500009","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503500009?lang=en_us&edition=fundamental","pubTime":"2025-01-15 02:05","pubTimestamp":1736877905,"startTime":"0","endTime":"0","summary":"Howmet Aerospace benefits from air travel growth and Boeing's gradual recovery. Defense stocks are acting well at large","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2025/01/sotd-for-01-14-2025-desktop-150x150.png","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/01/sotd-for-01-14-2025-desktop-150x150.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/ibd-stock-of-the-day/howmet-stock-buy-signal-aerospace-defense-shares-nearly-tripled/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU0096362180.USD","LU0823046577.USD","LU0957791311.USD","HWM","BK4590","IBD","BK4516","ERJ","FTAI","LU1815333072.USD","LU0061474960.USD","LU1435385759.SGD","LU0823046494.USD","LU2326559502.SGD","BK4551","BK4104","BK4564","LU0053671581.USD","LU1429558221.USD","BK4187","BK4585","BA","BK4588","RKLB"],"gpt_icon":1},{"id":"2503856500","title":"AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503856500","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503856500?lang=en_us&edition=fundamental","pubTime":"2025-01-15 00:22","pubTimestamp":1736871720,"startTime":"0","endTime":"0","summary":"AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of the overall drug and biotech sector in the past couple of months after Trump picked Robert F. Kennedy Jr., a vaccine skeptic, to be the next secretary of the Department of Health and Human Services, the agency that oversees the FDA.This, coupled with disappointing third-quarter sales and profits, guidance cuts and pipeline setbacks took a toll on the overall drug and biotech industry’s performance.The decline in AbbVie’s stock price and the drug/biotech sector’s downturn have left investors confused about whether to buy, hold or sell ABBV stock. Let’s understand the company’s strengths and weaknesses to better analyze how to play AbbVie’s stock amid the recent price decrease.AbbVie has been on an acquisition spree in the past couple of years, which is strengthening its pipeline. It has signed several M&A deals in the immunolog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-falls-8-3-months-162200440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0985320562.USD","LU0661504455.SGD","LU0006306889.USD","LU0545039389.USD","LU2360106947.USD","SG9999014906.USD","SG9999015945.SGD","SG9999018857.SGD","LU0354030511.USD","SG9999017495.SGD","LU2461242641.AUD","LU2265009873.SGD","LU0061475181.USD","LU1244550221.USD","LU0672654240.SGD","LU0708995401.HKD","LU1868836914.USD","IE00BJJMRZ35.SGD","LU2237443549.SGD","NVO","LU2361044949.HKD","LU0708994859.HKD","SG9999018865.SGD","LU1057294990.SGD","IE00BVYPNW00.USD","LU0106261372.USD","SGXZ51526630.SGD","LU1023059063.AUD","LU1127390331.HKD","ABBV","BK4559","LU1585245621.USD","LU0320765059.SGD","LU0795875169.SGD","LU1712237335.SGD","SG9999014898.SGD","SG9999001176.SGD","LU0471298777.SGD","LU0079474960.USD","LU1934455194.USD","LU1551013342.USD","BK4007","LLY","LU2237443382.USD","LU1934455277.USD","LU1934455863.HKD","IE00BVYPNV92.GBP","LU0158827948.USD","LU0234570918.USD","IBD"],"gpt_icon":1},{"id":"2503852085","title":"Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2503852085","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503852085?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:00","pubTimestamp":1736859600,"startTime":"0","endTime":"0","summary":"First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/14/3009229/0/en/Ventyx-Biosciences-Highlights-2025-Pipeline-Strategy-and-Provides-Clinical-Updates-on-its-NLRP3-Inhibitor-Portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","IBD","BK4007","VTYX"],"gpt_icon":0},{"id":"2503536374","title":"Planet Fitness, IBD Stock Of The Day, Flexes Near Buy Point With Membership Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2503536374","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503536374?lang=en_us&edition=fundamental","pubTime":"2025-01-14 01:44","pubTimestamp":1736790246,"startTime":"0","endTime":"0","summary":"Planet Fitness memberships rose despite the no-judgment gym operator's first fee hike in decades. Planet Fitness stock is near a buy point.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2025/01/sotd-for-01-13-2025-desktop-150x150.png","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/01/sotd-for-01-13-2025-desktop-150x150.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/ibd-stock-of-the-day/planet-fitness-stock-buy-point-membership-growth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU2210149790.SGD","LU0053671581.USD","IBD","LU2095319765.USD","BK4551","LU0266013472.USD","BK4216","LU2125909593.SGD","BK4532","LU2211815571.USD","PTON","BK4566","LU1878469433.USD","PLNT","BK4190","LU2210150020.SGD","LU0390134368.USD","LU1923622614.USD","LU2125909247.SGD","BK4548","LTH"],"gpt_icon":0},{"id":"2503302193","title":"Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2503302193","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503302193?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025. Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025. Phase 2 platform trial in ulcerative colitis  remains on track for initiation in mid-2025 with SPY001 , followed by SPY002 , SPY003 , and combinations thereof, with initial results expected in 2026. Strong balance sheet with preliminary cash, cash equivalents, and marketable securities balance of over $600M as of December 31, 2024*, anticipated to provide cash runway into the second half of 2028","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-highlights-2025-priorities-130000578.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-highlights-2025-priorities-130000578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","RA","IBD","BK4139","SYRE"],"gpt_icon":0},{"id":"2503230941","title":"Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2503230941","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503230941?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"–Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways –。–Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 in combination with pembrolizumab anticipated in fourth quarter of 2025 –。– Initiation of Phase 1/2 dose and regimen-finding clinical trial of WTX-330 expected in firstquarter of 2025 –。– Cash guidance provides runway through at least the second quarter of 2026 –。Werewolf continues to evaluate WTX-124 as a monotherapy and in combination with pembrolizumab through the ongoing Phase 1/1b clinical trial evaluating the INDUKINE molecule in multiple solid tumor types. WTX-124 has shown promising monotherapy activity and an improved tolerability profile versus high dose IL-2 in heavily pretreated patients refractory to all standard-of-care therapies, including immune checkpoint i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/werewolf-therapeutics-provides-business-highlights-130000639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HOWL","SITC","IBD","BK4139","BK4080","BK4539","LENZ","BK4231","RCC"],"gpt_icon":0},{"id":"2502058647","title":"Boston Scientific Tops All-Time High: See New Names On IBD 50, IPO Leaders, More","url":"https://stock-news.laohu8.com/highlight/detail?id=2502058647","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502058647?lang=en_us&edition=fundamental","pubTime":"2025-01-09 07:53","pubTimestamp":1736380383,"startTime":"0","endTime":"0","summary":"Find out which top-rated stocks like Boston Scientific have just earned a spot on IBD's lists of the best growth stocks.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate3-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate3-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/boston-scientific-tops-all-time-high-see-new-names-on-ibd-50-ipo-leaders-more/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU0077335932.USD","LU0011850046.USD","LU0238689110.USD","LU1804176565.USD","LU2087625088.SGD","LU2362541273.HKD","LU2506951875.HKD","IE00B2B36J28.USD","LU1718418525.SGD","LU0353189763.USD","LU2362541513.USD","IE0009355771.USD","LU0528227936.USD","LU0950375773.USD","LU2506952170.USD","IE00BJJMRZ35.SGD","IBD","BK4588","IE00B4R5TH58.HKD","LU0353189680.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0048584097.USD","LU0266013472.USD","LU0345769631.USD","BK4504","BK4585","LU1983299246.USD","BK4082","LU2112291526.USD","LU2324357040.USD","LU2491050154.USD","LU2506952097.USD","LU0251132253.USD","LU0823417653.USD","LU1989772840.SGD","IE00BFTCPJ56.SGD","LU0187121727.USD","LU0345769128.USD","LU0823417737.USD","LU2265009873.SGD","LU2244417387.USD","LU0267386448.USD","LU2506951958.HKD","LU0823416689.USD","LU2491049909.HKD","LU2491050071.SGD","LU1989764664.SGD","BSX","LU1061106388.HKD"],"gpt_icon":0},{"id":"2502087246","title":"Stock Market Seeks Direction, Grasps For Possible Support Levels; These IBD 50 Stocks Approach Buy Points","url":"https://stock-news.laohu8.com/highlight/detail?id=2502087246","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502087246?lang=en_us&edition=fundamental","pubTime":"2025-01-09 06:27","pubTimestamp":1736375272,"startTime":"0","endTime":"0","summary":"Of a handful of breakouts in the MarketSurge 250 index the past couple of weeks, about half remain above buy points.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2022/01/Stock-nyse-0122-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2022/01/Stock-nyse-0122-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/market-trend/the-big-picture/stock-market-sp500-nasdaq-dow-jones-direction/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4122","IBD","PCOM"],"gpt_icon":0},{"id":"2501114738","title":"IBD Stock Of The Day: Netflix Tests Key Level Ahead Of Q4 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2501114738","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501114738?lang=en_us&edition=fundamental","pubTime":"2025-01-08 01:15","pubTimestamp":1736270118,"startTime":"0","endTime":"0","summary":"Netflix stock is testing support at its 50-day line ahead of its Q4 earnings results","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2025/01/sotd-for-01-07-2025-desktop-150x150.png","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/01/sotd-for-01-07-2025-desktop-150x150.png"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/ibd-stock-of-the-day/netflix-stock-nflx-news-q4-earnings-preview-streaming/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IBD","NFLX"],"gpt_icon":1},{"id":"2501050226","title":"Nvidia, Netflix, TSMC New To These IBD Lists: Check Out Names On IBD 50, Stock Spotlight And More","url":"https://stock-news.laohu8.com/highlight/detail?id=2501050226","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501050226?lang=en_us&edition=fundamental","pubTime":"2025-01-07 08:07","pubTimestamp":1736208421,"startTime":"0","endTime":"0","summary":"See which stocks like Nvidia have just been added to – or removed from – IBD’s stock lists, including the IBD 50, Sector Leaders, IBD Big Cap 20 and IPO Leaders.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate2-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate2-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/check-out-names-on-ibd-50-stock-spotlight-and-more/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["NVD3.UK","LU0541502299.USD","NVDA","LU2077746001.SGD","2NVD.UK","LU1699723380.USD","IE00BK4W5M84.HKD","NVDX","LU1066051811.HKD","NVD","IE00BDCRKT87.USD","LU2237443978.SGD","SG9999001424.SGD","TSM","NFLX","ODD","NVDS.UK","NVDU","LU0979878070.USD","3NVD.UK","LU0889565833.HKD","LU2294711713.HKD","VIST","03145","NVDS","NVDY","SGXZ51526630.SGD","LU0868494708.USD","LU2213496289.HKD","LU1814569148.SGD","LU2326559502.SGD","LU1989772923.USD","LU0572940350.SGD","LU0256863902.USD","IBD","LU0689626769.HKD","SNVD.UK","NVD2.UK","BK4549","LU0127658192.USD","LU0882574139.USD","LU1496350502.SGD","NVIW.SI","LU0689472784.USD","NVDD","LU1211504680.USD","LU0109391861.USD","IE0034235303.USD"],"gpt_icon":0},{"id":"2501070298","title":"Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501070298","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501070298?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:59","pubTimestamp":1736200740,"startTime":"0","endTime":"0","summary":"AUSTIN, TX and DURHAM, NC, Jan.  06, 2025  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/06/3005009/0/en/Shattuck-Labs-Announces-Presentation-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732799900.SGD","LU0795875169.SGD","HCSG","STTK","LU2023251221.USD","LU1363072403.SGD","LU1548497426.USD","LU1668664300.SGD","LU1720051017.SGD","LU2357305700.SGD","LU0106261372.USD","BK4534","BK4139","LU2271345857.HKD","BK4581","BK4127","BK4137","IE00BZ1G4Q59.USD","IBD","LU0106831901.USD","LU0795875086.SGD","LU0912757837.SGD","LU1720051108.HKD","LU0314104364.USD","LU0006306889.USD","LU0267386448.USD","BK4585","LU0158827948.USD","LU1732800096.USD","BK4588","LU2089283258.USD","LU0320765646.SGD","LU2347655156.SGD","LU1989772840.SGD","LU0158827781.USD","LU1074936037.SGD","LU2111349929.HKD","LU0971096721.USD","BK4516","LU1989772923.USD","IE00BKVL7J92.USD","LU0225283273.USD","LU0098860793.USD","LU1162221912.USD","LU2089284900.SGD","BK4504","LU2028103732.USD"],"gpt_icon":0},{"id":"2501423999","title":"Press Release: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501423999","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501423999?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:05","pubTimestamp":1736168700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 06, 2025  -- Organovo Holdings, Inc. , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease  including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer.Mr. Staskey has worked for Danforth Advisors since 2021, working as Chief Financial Officer for clients such as Azitra, Inc., a biotechnology company developing novel dermatology therapeutic technologies. Norm has over 25 years working in capital market and M&A transactions most recently as a Managing Director in EY's  national transactions practice where he led or advised on several fortune 500 M&A deals for both domestic and cross-border transactions, and was involved in the merger of Dell Inc. and EMC Corporation as a member of the EY team. Norm has also worked on several recent M&A deals in the biotech industry.Organovo expects a Phase 2 study to demonstrate effectiveness of FXR314 in moderate to severe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","BK4139","ONVO"],"gpt_icon":0},{"id":"2500792181","title":"Baker Hughes, Nvidia Lead 18 IBD Watchlist Adds: Build Your Growth Stock List With These Screens","url":"https://stock-news.laohu8.com/highlight/detail?id=2500792181","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500792181?lang=en_us&edition=fundamental","pubTime":"2025-01-04 07:57","pubTimestamp":1735948653,"startTime":"0","endTime":"0","summary":"Here are today’s top growth stocks that have just been added to the IBD stock lists, including the IBD 50, IPO Leaders and the IBD Big Cap 20.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate3-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate3-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/build-your-growth-stock-list-with-these-screens/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["NVD2.UK","BK4097","AGX","LU0689472784.USD","IBD","LU0943347566.SGD","VRT.AU","BKR","LU0256331488.USD","2NVD.UK","BGSX","LU1923622614.USD","LU2264538146.SGD","LU1093756168.USD","IE00BQXX3C00.GBP","NVDS","LU0528227936.USD","NVDX","SGXZ51526630.SGD","SG9999015978.USD","NVDD","NVDA","LU2361044949.HKD","NVD3.UK","NVIW.SI","BK4585","LU0238689110.USD","LU2430703251.USD","NVDY","LU1571399168.USD","IE00B3M56506.USD","BK4532","LU1323610961.USD","NVD","VRT","LU0345770308.USD","LU0823421333.USD","NOW","IE00BDCRKT87.USD","3NVD.UK","NVDU","LU0072462426.USD","BK4566","LU0494093205.USD","IE00B1BXHZ80.USD","SNVD.UK","LU0308772762.SGD","LU0048584097.USD","NVDS.UK"],"gpt_icon":0},{"id":"2500127227","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2500127227","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500127227?lang=en_us&edition=fundamental","pubTime":"2025-01-04 06:20","pubTimestamp":1735942800,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease , today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 21,000 shares of common stock of Spyre to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on January 2, 2025 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  products by combining best-in-class antibody engineering, rational therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-222000096.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-222000096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","IBD","SYRE","BK4139"],"gpt_icon":0},{"id":"2500149278","title":"Why Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed Yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=2500149278","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500149278?lang=en_us&edition=fundamental","pubTime":"2025-01-03 23:47","pubTimestamp":1735919249,"startTime":"0","endTime":"0","summary":"The stock market finished the first trading day of the year in the negative territory—a fifth straight day, over the lack of catalysts to spark trading appetite.The Dow Jones Industrial Average was down the most by 0.36 percent, the S&P 500 decreased 0.22 percent, and the Nasdaq Composite dipped 0.16 percent.Ten companies also kicked off trading mirroring the broader market downturn. In this article, let's explore the reasons behind their decline.A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.Shares of Teva Pharmaceuticals fell for a third day on Thursday, shedding another 3.34 percent or 0.74 points to finish at $21.3 apiece, as investors awaited further developments on its schizophrenia treatment Tev’749.While the asset showed statistical improvement in schizophrenia symptoms during its Phase III trial, some experts raised concerns about the drug’s twice-daily dosing schedule, saying that","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-teva-pharmaceuticals-industries-ltd-154729405.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4584","TEVA","BK4566","BK4596","BK4557","BK4559","BK4007","IBD","BK4588"],"gpt_icon":0},{"id":"2500073969","title":"Carpenter Technology Stock Receives IBD Stock Rating Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2500073969","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500073969?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:24","pubTimestamp":1735853040,"startTime":"0","endTime":"0","summary":"Carpenter Technology saw its IBD SmartSelect Composite Rating jump to 96 Thursday, up from 94 the day before.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2017/03/IDS5-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/03/IDS5-150x150.jpg"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/carpenter-technology-stock-receives-ibd-stock-rating-upgrade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IBD","CRS"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":131,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2025-06-26","symbol":"IBD","amount":0.0953,"announcedDate":"2025-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-26","defaultRemindTime":1750944600000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-26","currency":"USD","dateTimestamp":1750910400000,"payDate":"2025-07-01"},{"date":"2025-05-23","symbol":"IBD","amount":0.0809,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-23","defaultRemindTime":1748007000000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-28","payableDate":"2025-05-23","currency":"USD","dateTimestamp":1747972800000,"payDate":"2025-05-28"},{"date":"2025-04-25","symbol":"IBD","amount":0.0799,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-25","defaultRemindTime":1745587800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-25","currency":"USD","dateTimestamp":1745553600000,"payDate":"2025-04-30"},{"date":"2025-03-27","symbol":"IBD","amount":0.092,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-04-01"},{"date":"2025-02-24","symbol":"IBD","amount":0.0728,"announcedDate":"2025-02-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{}}}